What is he best known for?
The fields of study he is best known for:
- Cancer
- Statistics
- Internal medicine
Peter F. Thall spends much of his time researching Internal medicine, Surgery, Clinical trial, Chemotherapy and Gastroenterology.
His Internal medicine study combines topics from a wide range of disciplines, such as Immunology and Oncology.
His Oncology research includes elements of Prostate cancer, Toxicity and Docetaxel.
His Surgery research incorporates themes from Medical physics and Sarcoma.
His Clinical trial study incorporates themes from Statistics, Sample size determination, Bayesian probability, Bayes' theorem and Intensive care medicine.
His Chemotherapy research is multidisciplinary, relying on both Survival rate and Cancer.
His most cited work include:
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (572 citations)
- Some covariance models for longitudinal count data with overdispersion. (370 citations)
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS (346 citations)
What are the main themes of his work throughout his whole career to date?
Peter F. Thall mainly investigates Internal medicine, Surgery, Oncology, Clinical trial and Transplantation.
As part of the same scientific family, he usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Leukemia.
His work deals with themes such as Cancer, Toxicity and Urology, which intersect with Surgery.
His Oncology study deals with Prostate cancer intersecting with Docetaxel.
The study incorporates disciplines such as Outcome, Bayes' theorem, Bayesian probability, Statistics and Intensive care medicine in addition to Clinical trial.
He has included themes like Immunology and Fludarabine in his Transplantation study.
He most often published in these fields:
- Internal medicine (45.37%)
- Surgery (26.59%)
- Oncology (25.61%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (45.37%)
- Oncology (25.61%)
- Bayesian probability (13.66%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Bayesian probability, Clinical trial and Transplantation are his primary areas of study.
His Internal medicine study frequently links to related topics such as Gastroenterology.
The Oncology study combines topics in areas such as Hematopoietic stem cell transplantation, Prostate cancer and Prospective cohort study.
He has researched Bayesian probability in several fields, including Mathematical optimization and Missing data.
His study in Clinical trial is interdisciplinary in nature, drawing from both Precision medicine, Bayesian hierarchical modeling, Progression-free survival and Patient subgroups.
His Transplantation study combines topics from a wide range of disciplines, such as Randomized controlled trial and Acute leukemia.
Between 2017 and 2021, his most popular works were:
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (305 citations)
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. (27 citations)
- Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. (25 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Statistics
- Internal medicine
His scientific interests lie mostly in Internal medicine, Oncology, Clinical trial, Randomized controlled trial and Transplantation.
His multidisciplinary approach integrates Internal medicine and Gene signature in his work.
His Oncology research integrates issues from Immune checkpoint, Blockade, T cell, Adverse effect and Disease.
His Clinical trial study integrates concerns from other disciplines, such as Logistic regression and Patient subgroups.
He interconnects Nuclear medicine and Intensity-modulated radiation therapy in the investigation of issues within Randomized controlled trial.
His Transplantation research is mostly focused on the topic Busulfan.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
